Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis

 Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis

Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis

Shots:

  • Sandoz to get WW rights to distribute & commercialize proposed biosimilar natalizumab in all markets following its approval. Polpharma Biologics will be responsible for development, manufacturing and supply of proposed biosimilar natalizumab
  • The focus of the agreement is to expand Novartis/Sandoz’s portfolio across small molecules, complex generics, biosimilars, and innovator therapies with the addition of proposed biosimilar natalizumab enabling patients to access patented and off-patent therapies
  • Natalizumab is a mAb targeting adhesion molecule α4-integrin, the first-in-class therapy for the treatment of MS and is the fifth proposed biosimilar in-licensed by Sandoz in 9 months  

Click here to­ read full press release/ article | Ref: Novartis | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post